Design, Synthesis and Antidiabetic Activity of Biphenylcarbonitrile‐Thiazolidinedione Conjugates as Potential α‐Amylase Inhibitors. Issue 9 (4th March 2021)
- Record Type:
- Journal Article
- Title:
- Design, Synthesis and Antidiabetic Activity of Biphenylcarbonitrile‐Thiazolidinedione Conjugates as Potential α‐Amylase Inhibitors. Issue 9 (4th March 2021)
- Main Title:
- Design, Synthesis and Antidiabetic Activity of Biphenylcarbonitrile‐Thiazolidinedione Conjugates as Potential α‐Amylase Inhibitors
- Authors:
- Rathod, Chirag H.
Nariya, Pankajkumar B.
Maliwal, Deepika
Pissurlenkar, Raghuvir R. S.
Kapuriya, Naval P.
Patel, Anilkumar S. - Abstract:
- Abstract: The α‐amylase inhibition has been considered as an effective therapeutic approach against chronic Type 2 Diabetes mellitus (DM). In the present study, a series of biphenylcarbonitrile‐thiazolidinedione conjugates have been synthesized and evaluated for their antidiabetic activity via α‐amylase inhibition. It was found that most of the conjugates (14 a –j ) exhibited significant α‐amylase inhibition activity compared to the standard drug Acarbose. Off these, compound 14 b, 14 c and 14 d were most potent with IC50 value 0.13 μM, 0.15 μM and 0.13 μM respectively. To ascertain ligand‐receptor interactions, the in silico molecular docking studies of these conjugates (14 a –j ) have been carried out into the Acarbose active site of barley (malt) α‐amylase enzyme. The results have shown fair corroboration between significant α‐amylase inhibition activity of 14 b, 14 c and 14 d and their docking scores compared to the standard drug Acarbose. This study demonstrated that biphenylcarbonitrile‐thiazolidinedione conjugate could be a plausible pharmacophore for targeting α‐amylase for the treatment of Type 2 Diabetes mellitus. Abstract : A series of biphenylcarbonitrile‐thiazolidinedione conjugates have been designed and synthesized. A molecular docking study and an investigation of the antidiabetic activity through α‐amylase inhibition were performed. It was found that most of the syntheized conjugates showed significant α‐amylase inhibition activity compared to the standardAbstract: The α‐amylase inhibition has been considered as an effective therapeutic approach against chronic Type 2 Diabetes mellitus (DM). In the present study, a series of biphenylcarbonitrile‐thiazolidinedione conjugates have been synthesized and evaluated for their antidiabetic activity via α‐amylase inhibition. It was found that most of the conjugates (14 a –j ) exhibited significant α‐amylase inhibition activity compared to the standard drug Acarbose. Off these, compound 14 b, 14 c and 14 d were most potent with IC50 value 0.13 μM, 0.15 μM and 0.13 μM respectively. To ascertain ligand‐receptor interactions, the in silico molecular docking studies of these conjugates (14 a –j ) have been carried out into the Acarbose active site of barley (malt) α‐amylase enzyme. The results have shown fair corroboration between significant α‐amylase inhibition activity of 14 b, 14 c and 14 d and their docking scores compared to the standard drug Acarbose. This study demonstrated that biphenylcarbonitrile‐thiazolidinedione conjugate could be a plausible pharmacophore for targeting α‐amylase for the treatment of Type 2 Diabetes mellitus. Abstract : A series of biphenylcarbonitrile‐thiazolidinedione conjugates have been designed and synthesized. A molecular docking study and an investigation of the antidiabetic activity through α‐amylase inhibition were performed. It was found that most of the syntheized conjugates showed significant α‐amylase inhibition activity compared to the standard drug Acarbose. This study provided an important contemplation about scaffold combination for targeting α‐amylase. … (more)
- Is Part Of:
- ChemistrySelect. Volume 6:Issue 9(2021)
- Journal:
- ChemistrySelect
- Issue:
- Volume 6:Issue 9(2021)
- Issue Display:
- Volume 6, Issue 9 (2021)
- Year:
- 2021
- Volume:
- 6
- Issue:
- 9
- Issue Sort Value:
- 2021-0006-0009-0000
- Page Start:
- 2464
- Page End:
- 2469
- Publication Date:
- 2021-03-04
- Subjects:
- α-amylase inhibitor -- antidiabetic activity -- molecular docking -- 2, 4-thiazolidinedione -- Type 2 Diabetes mellitus
Chemistry -- Periodicals
540.5 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2365-6549 ↗ - DOI:
- 10.1002/slct.202004362 ↗
- Languages:
- English
- ISSNs:
- 2365-6549
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3172.241000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22448.xml